Omeros (NASDAQ:OMER) Hits New 12-Month High – What’s Next?

Omeros Corporation (NASDAQ:OMER) shares reached a new 52-week high on Wednesday . The company traded as high as $18.23 and last traded at $18.2850, with a volume of 1217358 shares. The stock had previously closed at $17.19.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on OMER shares. Zacks Research lowered Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Weiss Ratings upgraded Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Finally, Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Omeros currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Omeros Trading Up 1.3%

The firm has a 50-day moving average of $11.52 and a two-hundred day moving average of $11.71. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of 14.55 and a beta of 2.54.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. As a group, equities analysts anticipate that Omeros Corporation will post -0.37 EPS for the current year.

Insider Activity

In other news, CAO David J. Borges sold 5,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $16.95, for a total value of $84,750.00. Following the sale, the chief accounting officer owned 5,000 shares in the company, valued at approximately $84,750. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. State of Wyoming bought a new stake in shares of Omeros in the fourth quarter valued at about $25,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Omeros in the 2nd quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Omeros during the fourth quarter valued at approximately $33,000. Assetmark Inc. acquired a new position in shares of Omeros in the first quarter valued at $38,000. Finally, Tower Research Capital LLC TRC lifted its position in Omeros by 829.6% in the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 11,971 shares during the period. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.